Model-based dosing for better survival after transplantation.
作者信息
Boelens Jaap Jan, Scordo Michael
机构信息
Department of Pediatrics, Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY.
Department of Pediatrics, Weill Cornell Medical College, New York, NY.
出版信息
Blood Adv. 2024 Dec 10;8(23):6064-6066. doi: 10.1182/bloodadvances.2024014236.
Abstract
摘要
相似文献
1
Model-based dosing for better survival after transplantation.基于模型的给药方案可提高移植后的生存率。
Blood Adv. 2024 Dec 10;8(23):6064-6066. doi: 10.1182/bloodadvances.2024014236.
2
Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study.隔日给予类固醇可促进生长，且不会对移植物存活或长期移植物功能产生不利影响。北美儿科肾移植协作研究报告。
Transplantation. 1996 Jan 15;61(1):31-6. doi: 10.1097/00007890-199601150-00008.
3
Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation.基于模型的精准剂量调整在儿科和年轻成年异体造血细胞移植患者中应用的阿仑单抗治疗。
Br J Clin Pharmacol. 2022 Jan;88(1):248-259. doi: 10.1111/bcp.14955. Epub 2021 Jul 18.
4
Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation.评估基于药代动力学指导的造血干细胞移植用白消安给药的测试剂量策略。
Biol Blood Marrow Transplant. 2019 Feb;25(2):391-397. doi: 10.1016/j.bbmt.2018.09.017. Epub 2018 Sep 19.
5
Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis.抗胸腺细胞球蛋白暴露与成人非亲缘造血细胞移植生存结局之间的关联：一项多中心、回顾性、药效学队列分析。
Lancet Haematol. 2017 Apr;4(4):e183-e191. doi: 10.1016/S2352-3026(17)30029-7. Epub 2017 Mar 16.
6
Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.接受造血干细胞移植的儿科患者可以从新型每日一次静脉注射白消安剂量列线图中大大受益。
Am J Hematol. 2017 Jul;92(7):607-613. doi: 10.1002/ajh.24734. Epub 2017 May 30.
7
Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation.接受静脉注射白消安进行造血干细胞移植的儿童中基于体重和年龄的剂量给药策略的临床比较。
Pediatr Transplant. 2015 May;19(3):307-15. doi: 10.1111/petr.12430. Epub 2015 Feb 9.
8
Costs and Outcomes with Once-Daily versus Every-6-Hour Intravenous Busulfan in Allogeneic Hematopoietic Cell Transplantation.异基因造血细胞移植中每日一次与每6小时一次静脉注射白消安的成本与疗效
Biol Blood Marrow Transplant. 2020 Jan;26(1):145-149. doi: 10.1016/j.bbmt.2019.09.008. Epub 2019 Sep 13.
9
Predictive value of pretransplantation cyclosporine pharmacokinetic studies on initial post-transplantation dosing in pediatric kidney allograft recipients.肾移植前环孢素药代动力学研究对小儿肾移植受者移植后初始给药剂量的预测价值
Pediatr Transplant. 2003 Apr;7(2):102-10. doi: 10.1034/j.1399-3046.2003.00025.x.
10
Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.肥胖患者异体干细胞移植中的药物剂量和监测。
Int J Clin Pharm. 2011 Dec;33(6):918-24. doi: 10.1007/s11096-011-9568-0. Epub 2011 Sep 29.
本文引用的文献
1
Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity.免疫固有性错误患者异基因造血细胞移植后，与白消安暴露和结果的关系。
Blood Adv. 2024 Oct 8;8(19):5137-5145. doi: 10.1182/bloodadvances.2024013275.
2
Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19-depleted pediatric haploidentical HCT for hematologic malignancy.兔抗胸腺细胞球蛋白 PK 对 TCR-αβ/CD19 耗竭的亲缘单倍体造血干细胞移植治疗血液系统恶性肿瘤后结局的影响。
Blood Adv. 2024 Dec 10;8(23):6003-6014. doi: 10.1182/bloodadvances.2024012670.
3
Individualized dose of anti-thymocyte globulin based on weight and pre-transplantation lymphocyte counts in pediatric patients: a single center experience.基于体重和移植前淋巴细胞计数的儿童患者个体化抗胸腺细胞球蛋白剂量：单中心经验。
Bone Marrow Transplant. 2024 Apr;59(4):473-478. doi: 10.1038/s41409-024-02206-5. Epub 2024 Jan 22.
4
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.确定阿基仑赛治疗侵袭性 B 细胞非霍奇金淋巴瘤后改善结局的最佳氟达拉滨暴露量。
Blood Adv. 2023 Sep 26;7(18):5579-5585. doi: 10.1182/bloodadvances.2023010302.
5
Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial.个体化剂量的抗胸腺细胞球蛋白在儿科无关供体异基因造血干细胞移植（PARACHUTE）中的应用：一项单臂、2 期临床试验。
Lancet Haematol. 2022 Feb;9(2):e111-e120. doi: 10.1016/S2352-3026(21)00375-6.
6
Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens.大样本自体和异基因造血细胞移植受者中马法兰的群体药代动力学：向个体化给药方案迈进。
Clin Pharmacokinet. 2022 Apr;61(4):553-563. doi: 10.1007/s40262-021-01093-z. Epub 2021 Dec 2.
7
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.氟达拉滨最佳的淋巴细胞耗竭与 CAR T 细胞治疗后的改善结果相关。
Blood Adv. 2022 Apr 12;6(7):1961-1968. doi: 10.1182/bloodadvances.2021006418.
8
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation.抗胸腺细胞球蛋白在 CD34+T 细胞耗竭的异基因造血细胞移植中的应用。
Blood Adv. 2022 Feb 8;6(3):1054-1063. doi: 10.1182/bloodadvances.2021005584.
9
CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation.CD4 + T细胞重建可预测急性移植物抗宿主病后的生存结局：一项双中心验证研究
Blood. 2021 Feb 11;137(6):848-855. doi: 10.1182/blood.2020007905.
10
Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation.早期 CD4+ T 细胞重建可预测异基因造血细胞移植后的结局。
Cytotherapy. 2020 Sep;22(9):503-510. doi: 10.1016/j.jcyt.2020.05.005. Epub 2020 Jul 1.
Zotero 插件